Search Results

to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases

GIPR/GLP-1R co-agonists  in metabolic diseases.

First complete genome sequence of lumpy skin disease virus directly from a clinical sample in South India Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Moreover, the dysregulation of TLR4 contributes to numerous diseases, which highlights the importance

suggests that Fgr interacts with arrestin-3 at multiple sites and is consistent with the locations of disease-associated

With this high-resolution, dynamic view of GPCR activation, scientists can better tackle diseases by

Schizophrenia Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

GPCR Activation and Signaling Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances

G protein-coupled receptors (GPCRs) have been shown to play integral roles in Alzheimer's disease pathogenesis

collaboration with Eli Lilly and Company to advance small molecule therapeutics for cardiometabolic diseases

early access to: Industry insights : GPCRs and mRNA in drug discovery; new strategies for inflammatory disease

Nordisk stops Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological disease

Mutations in G protein-coupled receptors (GPCRs) underlie numerous diseases.

distinct from odor perception, and may contribute to the pathogenesis of disorders including brain diseases

linked to the development of many serious pathologies, like depression, schizophrenia and Parkinson’s disease Side Effects of a Dopamine Agonist Therapy for Parkinson’s Disease: A Mini-Review of Clinical Pharmacology Guidelines for the First-Line Treatment of Restless Legs Syndrome/Willis–Ekbom Disease, Prevention and

whether these CB1 receptors contribute to pathways underlying skeletal muscle biological function and disease

unveil new dimensions of GPCR functionality and offer innovative approaches to treating a wide range of diseases

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases

extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease

Key realities pharmacologists face: Assays measure one slice of biology Disease physiology involves many

wakefulness LPA3 agonist-producing Bacillus velezensis ADS024 is efficacious in multiple neuroinflammatory disease

tyrosine kinase IGF1R and its associated GPCRs are co-regulated by the noncoding RNA NEAT1 in Alzheimer's disease

Specialized Pro-resolving Lipid Mediators and Resolution of Viral Diseases.

do not have drugs available in the clinic, opening the door to groundbreaking treatments for various diseases

Adhesion GPCRs Adhesion G Protein-Coupled Receptor Gpr126 (Adgrg6) Expression Profiling in Diseased Mouse

participates in inflammatory and immune responses that have been found to mediate apoptosis in autoimmune disease

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

agonism at the GLP-1R represents a promising strategy for optimizing therapeutic outcomes in metabolic diseases

neuroscience drugmaker Cerevel Therapeutics for $8.7 billion FDA approves two gene therapies for sickle cell disease

next-generation sequencing, have enabled the uncovering of associations between GPCR genetic variants and diseases